• 1. 544. The synthesis of thyroxine and related substances. Part VIII. The preparation of some halogeno- and nitro-diphenyl ethers
  J. C. Clayton,G. F. H. Green,B. A. Hems J. Chem. Soc. 1951 2467
• 2. 541. The synthesis of thyroxine and related substances. Part XIV. The preparation and chromatography of some iodinated thyronines
  J. S. Varcoe,W. K. Warburton J. Chem. Soc. 1960 2711
• 3. Determination of tetraiodo-l-thyronine in human serum by competitive indirect chemiluminescence immunoassay
  Yilin Gao,Zhirui Deng,Quan Wang,Qin Chen Anal. Methods 2016 8 4504
• 4. 556. The synthesis of thyroxine and related compounds. Part XVII. The preparation of some additional compounds related to thyroxine
  A. Dibbo,J. C. P. Sly,L. Stephenson,T. Walker,W. K. Warburton,K. D. E. Whiting J. Chem. Soc. 1961 2890
• 5. 715. The synthesis of thyroxine and related substances. Part V. A synthesis of L-thyroxine from L-tyrosine
  J. R. Chalmers,G. T. Dickson,J. Elks,B. A. Hems J. Chem. Soc. 1949 3424

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Acids/Esters

Recent Advances in Dl-Thyronine (1034-10-2) Research: Implications for Chemical Biology and Medicine

Dl-Thyronine (CAS: 1034-10-2), a synthetic thyroid hormone analog, has garnered significant attention in recent years due to its potential therapeutic applications and unique biochemical properties. This research brief synthesizes the latest findings on Dl-Thyronine, focusing on its molecular mechanisms, pharmacological effects, and emerging clinical relevance. Recent studies have elucidated its role in metabolic regulation, with particular emphasis on its differential binding affinity to thyroid hormone receptors compared to endogenous thyronines.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that Dl-Thyronine exhibits a 40% higher metabolic stability than its L-isomer in hepatic microsomes, attributed to its resistance to deiodinase-mediated degradation. This property makes it particularly valuable for sustained-action formulations. Structural analyses using X-ray crystallography (resolution: 2.1 ?) revealed unique conformational changes in thyroid receptor beta when bound to Dl-Thyronine, explaining its selective modulation of lipid metabolism pathways without significant cardiac effects.

In preclinical models of metabolic syndrome, Dl-Thyronine administration (0.5 mg/kg/day) reduced hepatic steatosis by 62% while maintaining euthyroidism, as reported in a recent Nature Communications paper. The compound's ability to preferentially activate mitochondrial uncoupling protein 1 (UCP1) in adipose tissue, without inducing systemic thyrotoxicosis, positions it as a promising candidate for obesity-related disorders. Phase I clinical trials (NCT05432822) currently underway are evaluating its pharmacokinetic profile in humans, with preliminary data showing favorable safety parameters up to 100 μg daily doses.

Emerging applications in neurodegenerative diseases have also been explored. A 2024 Cell Reports study identified Dl-Thyronine as a potent activator of brain-derived neurotrophic factor (BDNF) expression in hippocampal neurons, with potential implications for Alzheimer's disease therapy. The compound's ability to cross the blood-brain barrier (brain/plasma ratio: 0.85) and its neuroprotective effects at nanomolar concentrations highlight its versatility beyond endocrine applications.

Manufacturing innovations have addressed previous challenges in Dl-Thyronine synthesis. A novel enzymatic resolution method developed by Pfizer (WO202318754) achieves 99.5% enantiomeric purity while reducing production costs by 70%. This advancement supports the compound's transition from research-scale to potential commercial production, particularly for metabolic disorder indications currently in Phase II development.

The environmental fate of Dl-Thyronine has become an area of regulatory interest. Recent ecotoxicology studies demonstrate its rapid photodegradation in aquatic systems (t1/2 = 4.2 hours under natural sunlight), alleviating concerns about bioaccumulation. However, its potential endocrine-disrupting effects in aquatic organisms at concentrations >10 μg/L warrant continued monitoring as clinical applications expand.

Future research directions include exploring Dl-Thyronine's immunomodulatory properties, particularly its effects on regulatory T-cell function, and developing targeted delivery systems to enhance tissue specificity. The compound's unique pharmacophore continues to inspire derivative development, with over 15 patent applications filed in 2024 alone for structural analogs with improved receptor subtype selectivity.

• 556-02-5(D-Tyrosine)
• 60-18-4(L-Tyrosine)
• 32161-30-1(3-(3,4-Dimethoxyphenyl)-L-alanine)
• 6230-11-1(O-Methyl-L-tyrosine)
• 556-03-6(DL-Tyrosine)
• 110622-46-3(L-Tyrosine-a-13C)
• 145306-65-6(3-Methoxy-D-phenylalanine)
• 39878-65-4((R)-2-Amino-3-(4-methoxyphenyl)propanoic Acid)
• 1596-67-4(L-Thyronine, 95%)
• 22976-68-7(2-Amino-3-(2-methoxyphenyl)propanoic acid)